Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor03
NCT05489211Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of datopotamab deruxtecan in endometrial cancer (EC), gastric cancer (GC), metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, colorectal cancer (CRC), sponsored by AstraZeneca. Started Sep 2022; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
endometrial cancer (EC)gastric cancer (GC)metastatic castration-resistant prostate cancer (mCRPC)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05489211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489211.